A regulatory patchwork-human ES cell research oversight
Article Abstract:
A mixed reaction of positive and negative response over regulations of human embryonic stem (hES) cell research for creation of embryos and cloning research from different regions of the world that will determine the research would carry on further or not is presented. The diverse national and international positions on regulating hES cells, the extent to which these positions are likely to change and their potential influence on research are discussed.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Embryonic stem cells pace the heart
Article Abstract:
Transplanted cardiomyocytes derived from human embryonic stem (ES) cells is substitute for pacemaker cells in a swine model of atrioventricular block and how elcit is compatible with animal survival is described. Evidence of the graft integrated electromechanically within the recipient tissue is also mentioned.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Electromechanical integration of cardiomyocytes derived from human embryonic stem cells
Article Abstract:
An attempt is made to investigate whether cells derived from human embryonic stem (hES) cells can restore myocardial electromechanical properties. The potential of hES-cell cardiomyocytes to act as a rate-responsive biological pacemaker and for future myocardial regeneration strategies are also mentioned.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells
- Abstracts: TeGenero fiasco prompts regulatory rethink. Germany reattempts to spark innovation. Humboldt University beefs up technology transfer
- Abstracts: Disclosure quality and the excess value of diversification. Discussion of accounting discretion in fair value estimates: an examination of SFAS 142 goodwill impairments
- Abstracts: The changing attitude of European VCs. Next-generation monoclonals less profitable than trailblazers?
- Abstracts: Biotech's knowledge trust. Probity gone nuts